Patents
Animal tissue with carbohydrate antigens compatible for human transplantation
Patent Number: 7,126,039This patent teaches ways of inactivating xenogeneic carbohydrate antigens and replacing them with non-immunogenic antigens so that various porcine and animal tissue may be transplanted into humans without the fear of hyperacute rejection. Since the problem of allogeneic rejection is still an issue, the clinical translation of this technology will most likely be long-term. Specifically, if it...
Inventors: Denning; Chris (Loughborough, GB), Clark; A. John (Midlothian, GB), Schiff; J. Michael (Menlo Park, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Sunday March 11th, 2001
Progenitor cell materials and methods
Patent Number: 7,125,714This patent covers a stem cell that expresses both CD34 and VEGFR-3. What is nice about this patent is that it covers cells with CD34 and VEGFR-3 from ANY source.
Inventors: Alitalo; Kari (Helsinki, FI), Joukov; Vladimir (Boston, MA)
Assignee: Licentia Ltd. (Helsinki, FI); Ludwig Institute for Cancer Research (New York, NY)
Date of First Priority Issue: Wednesday February 5th, 1997
Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
Patent Number: 7,118,748This patent covers the use of angiogensinogen I, II and specific derivatives for stimulation of hematopoietic and stem cell proliferation.
Inventors: Rodgers; Kathleen E. (Long Beach, CA), diZerega; Gere S. (Pasadena, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Thursday May 8th, 1997
Vitro engineered, regenerated urinary tract tissue compositions and methods for producing same
Patent Number: 7,122,200This patent covers ways of generating an artificial urinary tract through tissues engineering and culture of stem cells.
Inventors: Kropp; Bradley P. (Edmond, OK), Cheng; Earl Y. (Edmond, OK), Zhang; Yuan Yuan (Edmond, OK), Cowan; Rick (Oklahoma City, OK), Moore; Peter (Perry, OK)
Assignee: The Board of Regents of the University of Oklahoma (Norman, OK)
Date of First Priority Issue: Friday December 8th, 2000
Conditioned cell culture medium compositions and methods of use
Patent Number: 7,118,746This patent covers protection of keratinocytes from a variety of stresses by administration of conditioned media from a variety of stem cell sources. This patent is useful for cosmetics and also for skin regeneration.
Inventors: Naughton; Gail K. (Del Mar, CA), Horwitz; David L. (San Diego, CA), Applegate; Mark A. (San Diego, CA), Zeltinger; Joan (San Diego, CA), Mansbridge; Jonathan N. (La Jolla, CA), Kern; Andreas (San Diego, CA), Landeen; Lee K. (San Diego, CA), Ratcliffe; Ant
Assignee: SkinMedica, Inc. (Carlsbad, CA)
Date of First Priority Issue: Friday May 12th, 2000
Preparation and xenotransplantation of porcine islets
Patent Number: 7,122,177This patent covers the use of xenogeneic islet cells derived from fetal or neonatal pigs -20 to +10 days after birth, treating the cells with nicotinamide, lignocaine and a quinolone antibiotic, in order to generate a population of cells that may be encapsulated and used for treatment of diabetes in a human.
Inventors: Elliott; Robert Bartlett (Auckland, NZ), Calafiore; Riccardo (Perugia, IT), Basta; Gusseppe (Perugia, IT)
Assignee: Diabcell PTY Ltd. (Parkside, AU)
Date of First Priority Issue: Thursday January 20th, 2000
Mesenchymal precursor cell
Patent Number: 7,122,178This patent covers a progenitor cell that gives rise to mesenchymal stem cells. The population appears to be highly expressing the marker STRO-1, capable of differentiating into fibroblasts, and have at least one of the following markers: THY-1, VCAM-1, STRO-2, and CD146. These cells are claimed in this patent for augmentation of hematopoiesis. It will be interesting to compare this patent...
Inventors: Simmons; Paul (Kew, AU), Zannettino; Andrew (Highbury, AU), Gronthos; Stan (Bethesda, MD)
Assignee: Angioblast Systems, Incorporated (New York, NY)
Date of First Priority Issue: Wednesday July 7th, 1999
Composition and method for preserving progenitor cells
Patent Number: 7,112,653This patent covers peptides that inhibit hematopoietic stem cell proliferation, thereby allowing protection of these cells from chemotherapy or radiotherapy. This patent may conceptually be applicable to selectively inhibiting healthy stem cells while allowing leukemic stem cells to proliferate so that chemotherapy or radiotherapy may selectively kill the proliferating leukemic cells.
Inventors: Moore; Jeffrey G. (Kennebunkport, ME)
Assignee: Inclone Systems, Incorporated (New York, NY)
Date of First Priority Issue: Monday December 9th, 1996
Small organic molecule regulators of cell proliferation
Patent Number: 7,115,653This is a composition of matter patent on compounds that modulate hedgehog signalling. Since hedgehog is important not only in stem cell proliferation, but also in cancer, this patent has uses both in regeneration and cancer control.
Inventors: Baxter; Anthony David (Hertfordshire, GB), Boyd; Edward Andrew (Oxfordshire, GB), Frank-Kamenetsky; Maria (Brookline, MA), Guicherit; Oivin (Belmont, MA), Porter; Jeffery (Lexington, MA), Price; Stephen (Hartford, GB), Rubin; Lee L. (Wellesley, MA), Stibb
Assignee: Curis, Inc. (Cambridge, MA)
Date of First Priority Issue: Thursday March 30th, 2000
HoxD3 and HoxA3 compositions and methods for improved wound healing
Patent Number: 7,115,582This patent covers the use of HoxA3, and peptides, and nucleic acids derived from it for tissue regeneration. One particular use is the acceleration of wound healing, particularly for diabetes.
Inventors: Boudreau; Nancy (San Francisco, CA), Young; David M. (Larkspur, CA), Myers; Cornelia (San Francisco, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Thursday June 21st, 2001